Viridian Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
VRDN Nasdaq 2836 www.viridiantherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Viridian Therapeutics, Inc.

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says - Sep 22nd, 2026 9:45 am
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Sep 2nd, 2026 2:00 pm
Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says - Aug 7th, 2026 10:05 am
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Aug 6th, 2026 5:01 am
Graves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight - Jul 29th, 2026 8:31 am
Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN) - Jul 15th, 2026 8:01 am
Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich? - Jul 15th, 2026 6:24 am
Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today - Jul 14th, 2026 11:10 pm
“Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market - Jul 14th, 2026 11:55 am
Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone - Jul 6th, 2026 11:21 am
Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says - Jun 30th, 2026 9:53 am
Viridian may have edge over Amgen in eye drug showdown, analysts argue - Jun 30th, 2026 5:33 am
Comcast, Viridian Therapeutics jump premarket; Doximity slips - Jun 29th, 2026 6:09 am
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Jun 26th, 2026 4:57 pm
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease - Jun 26th, 2026 4:00 pm
Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M - May 21st, 2026 7:30 am
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - May 17th, 2026 12:52 pm
Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising - May 8th, 2026 2:18 am